TrialBlood advances2022

Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.

Paul M Barr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.